SCHEMBL2492016

SCHEMBL2492016

O=C(Cc1ccccc1)Nc1ncncn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.58
DEGS1 O15121 1/20 0.53
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
HDAC8 Q9BY41 2/20 0.52
HDAC6 Q9UBN7 2/20 0.52
CCNE1 P24864 4/20 0.50
CDK2 P24941 4/20 0.50
CDK5 Q00535 4/20 0.50
HPGD P15428 3/20 0.50
KDM6B O15054 1/20 0.50
KDM4D Q6B0I6 1/20 0.50
KDM4C Q9H3R0 1/20 0.50
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
ALDH1A1 P00352 2/20 0.49
GAA P10253 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4557710 0.79 DEGS1 (0.60) EPHX2DEGS1MEN1KMT2AKDM6B
SCHEMBL13934555 0.76 EPHX2 (0.53) EPHX2DEGS1MEN1KMT2AHDAC8
SCHEMBL822338 0.75 TSHR (0.59) EPHX2MEN1KMT2AHDAC8HDAC6
Benzene SCHEMBL11566961 0.74 EPHX2 (0.76) EPHX2MEN1KMT2AKDM6BKDM4D
SCHEMBL2205445 0.74 EPHX2 (0.76) EPHX2MEN1KMT2AKDM6BKDM4D
SCHEMBL1516167 0.74 EPHX2 (1.00) EPHX2MEN1KMT2AHDAC8HDAC6
SCHEMBL2489636 0.74 ALDH1A1 (0.42) EPHX2MEN1KMT2ANPC1RAB9A
SCHEMBL4203468 0.73 EPHX2 (0.54) EPHX2DEGS1MEN1KMT2AHDAC8
SCHEMBL30378242 0.73 EPHX2 (0.54) EPHX2DEGS1MEN1KMT2AHDAC8
SCHEMBL16061776 0.73 EPHX2 (0.50) EPHX2DEGS1MEN1KMT2AHDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3325481-A1 COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO KIT AND PDGFR Blueprint Medicines Corporation (US) 2018-05-30 EP disclosed
WO-2017019442-A1 COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO KIT AND PDGFR BLUEPRINT MEDICINES CORPORATION (US) 2017-02-02 WO disclosed
EP-2550257-A1 PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES Lead Discovery Center GmbH (DE) 2013-01-30 EP disclosed
WO-2011116951-A1 PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES LEAD DISCOVERY CENTER GMBH (DE) 2011-09-29 WO disclosed